Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
October 23rd 2023Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.
Read More